Founder and CSO Steven Prestrelski resigns, becomes Senior Scientific Advisor at Xeris Biopharma

Xeris Biopharma Holdings, Inc.

Steven Prestrelski, PhD, Founder and Chief Scientific Officer, resigned effective June 30, 2023.
He entered a consulting agreement as Senior Scientific Advisor from July 1, 2023 to January 31, 2025.
The consulting agreement covers predefined services; no further financial terms disclosed.
Transition follows founder's departure from executive role but retention as advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.